Skip to main content

Free Content Incidence of ethambutol-related visual impairment during treatment of active tuberculosis [Review article]

Download Article:
 Download
(PDF 457 kb)
 

Abstract:

BACKGROUND: Recent World Health Organization guidelines recommend the addition of ethambutol (EMB) throughout standardised treatment of new cases of active tuberculosis (TB) in populations with increased prevalence of isoniazid resistance to reduce the risk of creating multidrug resistance. This could expose patients to the risk of blindness.

METHODS: We searched Cochrane, Embase and PubMed electronic databases from 1965 to February 2011 for original studies that prospectively followed all patients treated with EMB for active TB, and routinely ascertained the occurrence of visual toxicity using standard methods. Pooled estimates, overall and stratified by major covariates, were calculated using random effects meta-analysis.

RESULTS: Pooled cumulative incidence of any visual impairment in all patients was 22.5 per 1000 persons treated with EMB (95%CI 10.2–35), and permanent impairment was 4.3/1000 (95%CI 0.3–9.0). After restricting the analyses to arms in which the average dose was 27.5 mg/kg/day or less and treatment was for 2–9 months, the incidence of any visual impairment was 19.2/1000 (95%CI 5.8–33), and permanent impairment was 2.3/1000 persons (95%CI 0–6.1) treated, as the majority of episodes were reversible. In reversible cases, resolution of impairment occurred after an average of 3 months.

CONCLUSIONS: In this review, any visual impairment occurred in 22.5/1000 persons receiving EMB at standard doses for up to 9 months, and permanent impairment in 2.3/1000—an important risk. However, these estimates are imprecise, and the studies were of variable quality and the results heterogeneous. Well-designed prospective studies with repeated measurements of multiple visual parameters that clearly describe the degree of permanent impairment are needed.

Keywords: blindness; eye toxicity; meta-analysis; systematic review; tuberculosis treatment

Document Type: Research Article

DOI: http://dx.doi.org/10.5588/ijtld.11.0766

Affiliations: 1: Respiratory and Epidemiology Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Canada 2: Department of Ophthalmology, McGill University, Montreal, Canada

Publication date: April 1, 2013

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
iuatld/ijtld/2013/00000017/00000004/art00005
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more